Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the safety of intravitreal (IVT)
REGN2176-3 in patients with neovascular wet age-related macular degeneration (AMD).